{"name":"ChemGenex Pharmaceuticals","slug":"chemgenex-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Homoharringtonine","genericName":"Homoharringtonine","slug":"homoharringtonine","indication":"Chronic myeloid leukemia","status":"phase_3"}]}],"pipeline":[{"name":"Homoharringtonine","genericName":"Homoharringtonine","slug":"homoharringtonine","phase":"phase_3","mechanism":"Small molecule","indications":["Chronic myeloid leukemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPanZXbGFndUFsQmlWMlZZdEI1ckdLbHJ6akJxM0kxendtRFNKMWRBZmdidE5HMlh6blQwZlk0cENMbngyRXZzWmpJb2R3NjJneGlzYVJnNzVfSHI4cXdVYi1HQkdsUDQzclp2eFNuc0dUbG5xdVpvYlJSNGxWNXRVSG1PVnBQcmNXUDM1WmhEeno4ZDhON2FJRHdvUzdUOThvZHJuYUFwN01sTGR1NGc?oc=5","date":"2023-01-23","type":"pipeline","source":"citybiz","summary":"Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors - citybiz","headline":"Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFAzNWdxUkw5bURJSkZadlpDSHkxV1VmamhNT2JfVTRrQ25oMjZFUG56LU96eDJ4ak0zM1NMMzZTV0oxNExKMktwZ0lydnh2WXlmSG1KYS1QX1FFQjZlQ3JfTEFrZjlCSlp1dm9CMW5wbnFqN3B5Zmc?oc=5","date":"2014-12-15","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Top 17 Serial Bio Entrepreneurs - Genetic Engineering and Biotechnology News","headline":"Top 17 Serial Bio Entrepreneurs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9ZRHpYeHI3bU9mTGRjNkhMd0w2bUU5aEdycFA2SFRReDMzNE4tZVpNdzFLaHlIeEJEWWtvWE5lYnZwMjJzalNlal8wdV9Md0RaaUFERExTYnBhQ0pzNnpfS2tIMWh2MG51aVo3QVpjRkExMHlranV6ZW1R?oc=5","date":"2011-05-03","type":"pipeline","source":"Pharmafile","summary":"Cephalon accepts Teva’s $6.8 billion white knight bid - Pharmafile","headline":"Cephalon accepts Teva’s $6.8 billion white knight bid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOLVRQdWJyM1BNT2JxRk5HMUtSOC04M3hPRU5RclNKdGVKMWZOY2p5MmR0bDBLd210c050al9wT0xqSEFfZnR5anotOFU2MUx5dF9vTjRjZl8ySktUODIxVFQ5RVNxMTY0SWdlT1JHcFZkWnhRQVN1SlQ4SmZkWG5zamQzS0dNU1lpZjRLeHlzXzI0eTR1OHBpQS1tZFk4UjNfV1E4R09B?oc=5","date":"2011-03-30","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Valeant Takes Unsolicited $5.7M Cash Offer for Cephalon to Shareholders - Genetic Engineering and Biotechnology News","headline":"Valeant Takes Unsolicited $5.7M Cash Offer for Cephalon to Shareholders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOZWYwQW95eWJVYXZxNi1SOFB1UU04QmVJQjdCWVh4dE56Mk5yNU9OaExGX0VpNjVyYmM4YU5EcGJzTmlhMUpCNUUzRXhLek5xcEpXNEN4a0wyb2NvSDJOM2ktTFA3M1FkMjAwRUYxa0lGSHZMVUNYUWUtbElhRmxreGx3aVJDdTl6TlJUMVR4U1JxcHhxb1ZxTUVNemE5OXN4bkthQzZ2WTZBT2p1?oc=5","date":"2011-03-29","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Cephalon Makes $231M Overall Bid to Acquire ChemGenex for NDA-Ready CML Drug - Genetic Engineering and Biotechnology News","headline":"Cephalon Makes $231M Overall Bid to Acquire ChemGenex for NDA-Ready CML Drug","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}